[breadcrumb_custom]

Viking Therapeutics Inc (NASDAQ: VKTX) Gain 5.85%, Marking A Loss For Bears.

In the last trading session, 4.96 million Viking Therapeutics Inc (NASDAQ:VKTX) shares changed hands as the company’s beta touched 0.57. With the company’s per share price at $30.58 changed hands at $1.69 or 5.85% during last session, the market valuation stood at $3.07B. VKTX’s last price was a premium, traded about 3.7% off its 52-week high of $29.45. The share price had its 52-week low at $8.28, which suggests the last value was 72.92% up since then. When we look at Viking Therapeutics Inc’s average trading volume, we note the 10-day average is 3.77 million shares, with the 3-month average coming to 1.75.

Viking Therapeutics Inc (NASDAQ:VKTX) trade information

Instantly VKTX was in green as seen at the end of in last trading. With action 30.41%, the performance over the past five days has been green. The jump to weekly highs of 32.00 added 5.85% to the stock’s daily price. The company’s shares are showing year-to-date upside of 64.32%, with the 5-day performance at 30.41% in the green. However, in the 30-day time frame, Viking Therapeutics Inc (NASDAQ:VKTX) is 41.12% up. Looking at the short shares, we see there were 12.92 million shares sold at short interest cover period of 4.78 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Viking Therapeutics Inc (VKTX) estimates and forecasts

Data shows that the Viking Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 105.51% over the past 6 months, a -24.18% in annual growth rate that is considerably lower than the industry average of 15.50%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Viking Therapeutics Inc will fall -8.00%, while the growth in revenue is estimated to hit -47.40% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -18.89%. The 2024 estimates are for Viking Therapeutics Inc earnings to decrease by -24.51%, but the outlook for the next 5-year period is at 40.00% per year.

On Key

Related Posts